옵션 체인은 다양한 행사가격과 만기일에 대한 180 Life Sciences의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 180 Life Sciences에 대한 시장 심리를 평가합니다..

180 Life Sciences (NASDAQ:ATNF) 주식, 옵션 체인

180 Life Sciences

180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.

180 Life Sciences Corp

Becton Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) lowered its fiscal year 2025 guidance and provided an <a href="https://www.benzinga.com/pressreleases/25/05/n45128945/bd-reports-second-quarter-fiscal-2025-financial-results" target="_blank" rel="noreferrer noopener">estimated tariff impact </a>on Thursday.
The medical device company reported adjusted earnings per share of $3.35, up from $3.17 a year ago. It beat the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of $3.28</a>.
The company reported first-quarter 2025 sales of $5.27 billion, up 4.5% year-over-year, missing the consensus of $5.35 billion.
Becton Dickinson expects fiscal 2025 revenues of $21.8 billion and $21.9 billion. Its previously issued guidance of $21.7 billion to $21.9 billion reflects updated organic revenue growth guidance of 3.0% to 3.5% and an improvement in the <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">estimated impact of foreign currency</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
Goldman Sachs on Friday downgraded Becton Dickinson from Buy to Neutral, revising its <a target="_blank" href="https://www.benzinga.com/quote/BDX/analyst-ratings" rel="noreferrer noopener">price target from $256 to $192</a>.
Analyst David Roman says BDX stock has fallen 25% since being added to the Buy list on May 30, 2024, compared to the S&amp;P500&#8217;s 6% and their large-cap MedTech coverage of 5%.
&#8220;We think the underperformance reflects downward revisions in organic growth estimates despite ongoing strong P&amp;L results. Specifically, the forward outlook for organic revenue growth has shifted from ~5-6% two years ago to ~3-4%. This level of organic growth puts BD at the low-end of MedTech,&#8221; Roman added.
Goldman Sachs says because Becton Dickinson has a large share of its market, its growth is closely tied to how fast the overall market is growing. As the market has slowed, so have Becton Dickinson&#8217;s growth targets.
Some of these market challenges may ease over time. But Roman is less confident that Becton will return to steady mid-single-digit organic revenue growth by fiscal year 2026 — a key part of the investment case.
William Blair on Thursday downgraded Becton Dickinson to Market Perform following a disappointing fiscal second-quarter update.
&#8220;We have been wrong with our rating on this stock for several years, holding out hope that shares would see multiple expansion once the business found a new gear that resulted in more predictable revenue growth, margin expansion, and earnings growth,&#8221; analyst Andrew Brackmann writes.
William Blair writes that Becton, at its core, has the makeup to drive mid-single-digit revenue growth over an extended period.
However, that is not the case right now, making the near-term setup challenging— especially as the Bioscience and Diagnostics business is set to be separated but for which those businesses are seeing increased headwinds.
The analyst seeks greater confidence in a reacceleration in organic growth and looks to fiscal 2026 guidance and updates on the Bioscience and Diagnostics separation as key catalysts over the coming months.
Stifel maintains Becton Dickinson with a Buy, lowering the price target from $280 to $224.
Piper Sandler downgrades Becton Dickinson from Overweight to Neutral and lowers the price target from $260 to $185.
Price Action: BDX stock is down 1.36% at $167.24 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45171306/magna-shares-fall-as-profit-miss-overshadows-strong-sales-higher-outlook" target="_blank" rel="noreferrer noopener">Magna Shares Fall As Profit Miss Overshadows Strong Sales, Higher Outlook</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Large Cap

News

Guidance

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, "The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC"
FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>), a company improving health through innovative tests that guide patient care, will share new data on its TissueCypher Barrett's Esophagus test via two posters at the Digestive Disease Week&#xAE; (DDW 2025) Annual Meeting, being held May 3-6 in San Diego. In addition to the product theater, Castle is collaborating with renowned gastrointestinal (GI) experts and the American Society for Gastrointestinal Endoscopy (ASGE) on several educational sessions highlighting the use of TissueCypher to improve the risk stratification and subsequent management of patients with Barrett's esophagus (BE).

CSTL

Castle Biosciences To Share New Data at DDW 2025 Highlighting TissueCypher Test's Ability To Identify Patients At Increased Risk For Developing Esophageal Cancer

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has outperformed the market over the past 5 years by 58.55% on an annualized basis producing an average annual return of 73.19%. Currently, NVIDIA has a market capitalization of $2.79 trillion. 
Buying $1000 In NVDA: If an investor had bought $1000 of NVDA stock 5 years ago, it would be worth $15,712.45 today based on a price of $114.50 for NVDA at the time of writing.
<h3>NVIDIA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746217812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

Here's How Much You Would Have Made Owning NVIDIA Stock In The Last 5 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 30.89% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 28.91% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 20.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 20.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 18.89% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 13.34% at $0.23</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 12.22% at $1.00</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 9.65% at $1.25</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 8.51% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 7.32% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 5.37% at $1.41</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 4.44% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 4.25% at $10.64</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 3.67% at $6.49</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 3.59% at $7.79</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed up 3.42% at $166.78</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.33% at $0.11</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.05% at $1.36</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 34.01% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 30.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 23.68% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 8.98% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 8.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 6.59% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 5.67% at $1.33</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.27% at $0.46</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 5.16% at $0.41</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 4.44% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.42% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 4.17% at $0.71</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 4.07% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 3.57% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 3.45% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 3.23% at $0.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

BLOZF

CLSH

CNBX

CNTMF

CPHRF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CXXIF

ELLXF

FUAPF

GNLN

GRWG

GTBIF

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MRMD

NWVCF

OILFF

RMHB

RSSFF

SOLCF

TGIFF

TLRY

UGRO

XXII

ZDPY

Marijuana Stock Movers For May 2, 2025

<a href="https://www.bloomberg.com/news/articles/2025-05-02/nike-adidas-call-on-trump-to-exempt-footwear-from-tariffs">https://www.bloomberg.com/news/articles/2025-05-02/nike-adidas-call-on-trump-to-exempt-footwear-from-tariffs</a>

ADDYY

'Nike, Adidas Call on Trump to Exempt Footwear From Tariffs'- Bloomberg

Donald Trump and the Republicans won control of the presidency, the House of Representatives and the Senate in<a href="https://www.benzinga.com/personal-finance/financial-advisors/24/11/41868686/how-trumps-win-will-change-tax-planning"> the 2024 election.</a> With Republican control, an extension of the 2017 tax bill was expected to be a priority, but it is moving slowly.
What Happened: Many Americans want to know what the impact of <a href="https://www.benzinga.com/topic/tariffs">tariffs from President Donald Trump</a> means for their future finances.
Americans should also be bracing for the potential end of the Tax Cuts and Jobs Acts (TCJA), which passed in 2017.
The TCJA expires on Dec. 31, 2025, and without an extension from Congress, it would revert some tax cuts and laws to 2018, as reported by <a href="https://www.kitces.com/blog/tax-cuts-and-jobs-act-tcja-sunset-budget-resolution-reconciliation-salt-cap-qbi-deduction-congress-republication-house-senate-bill/?utm_source=ActiveCampaign&amp;utm_medium=email&amp;utm_content=Analyzing%20Congressional%20Republicans%20%20Budget%20Proposal%20For%20The%202025%20TCJA%20Extension%20%5BNEV%5D&amp;utm_campaign=NEV%20Wednesday%20Email&amp;vgo_ee=e3zZ%2FKe5aZwXdWyRjOitaVxTcjhkmETgNoT9twI3pWYz%3A9835skIv0piXRPBo79MbCvS%2Fl9xkoTkI">Kitces</a>.  
What this means for the average American is that tax brackets could change, and the Child Tax Credit and other common tax breaks could also go away. These are items currently operated under the TCJA.
More importantly, this would mean a moderate tax increase for most households, according to the report.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050225">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Congress has been making slow progress in the extension of the TCJA, according to the report. The House and Senate also have differing versions when it comes to tax cuts.
The House of Representatives&#8217; version includes $4.5 trillion of tax cuts over the next 10 years. This would mostly cover the $4.6 trillion needed to extend the TCJA, but would leave little room for additional tax cuts.
This means the House would have to change the number of years or make changes to keep all current tax cuts in place and add items Trump campaigned for, such as no taxes on tips.
The Senate's version of tax cuts includes $1.5 trillion in tax cuts done with an accounting tactic that places $0 value on the existing TCJA, according to the report. This means the Senate version would see TCJA rules permanent and add room for additional tax cuts.
Congress still has time to figure things out, but without enacting an extension of the TCJA before the December deadline, things could look much different for Americans in 2026.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/25/04/45111571/trump-100-days-if-you-invested-1000-in-spy-qqq-bitcoin-when-trump-was-inaugurated-heres-how-much-youd-have-today">Trump 100 Days: If You Invested $1,000 In SPY, QQQ, Bitcoin When Trump Was Inaugurated, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Personal Finance

Tax Cuts And Jobs Act Could Expire At End Of 2025 Without Congressional Extension: What This Means For You

A leading provider of cloud networking solutions, Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) commands strong relevance. Thanks to its focus on high-speed Ethernet switches and routers designed for data centers, cloud computing environments and enterprise networks, Arista forms the backbone of modern cloud services. Unfortunately, competitive pressures combined with uncertainty over President Donald Trump's trade policies have negatively impacted ANET stock. Recently, though, sentiment across the board is shifting.
Earlier this week, Rosenblatt analyst Mike Genovese <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/45071063/this-arista-networks-analyst-is-no-longer-bearish-here-are-top-2-upgrades-for-tuesday">upgraded ANET stock</a> to Neutral from Sell, while also raising the price target to $85 from the prior forecast of $55. On the color commentary side, CNBC's Jim Cramer <a href="https://www.benzinga.com/25/04/44976958/jim-cramer-arista-networks-is-down-way-too-much-likes-uber-very-much">pounded the table</a> on ANET last week when the security was trading hands at $70, noting that the stock was "down way too much."
With ANET stock rapidly approaching the $92 level at time of writing, the natural inclination is to believe prospective traders are late to the party. However, data from the smart money suggests otherwise. Earlier today, Benzinga's <a href="https://www.benzinga.com/insights/options/25/05/45172353/decoding-arista-networkss-options-activity-whats-the-big-picture">options scanner identified unusual activity</a> in the derivatives arena, with a particular focus on bullish sentiment transactions.
Two factors immediately stood out. First, all of the trades identified as bullish were call options, meaning that they represent debit-based transactions. In other words, traders pay a debit under the assumption that a future event will materialize. By logical deduction, the security must rise to meet minimum profitability thresholds.
Second, the debit calls were all sweep transactions. Essentially, sweeps represent the institutional version of the market order, which emphasizes transaction speed over extracting the best (lowest) premium price. Therefore, it's reasonable to assume that the smart money was in a hurry to position themselves for additional upside.
In the near term, that moment can arrive next Tuesday after the closing bell when Arista discloses its first-quarter earnings report. Stronger-than-expected results or even an encouraging outlook could potentially send ANET stock northward.
<h2 class="wp-block-heading">Market Demand Profile for ANET Stock Incentivizes Speculation</h2>
In the film "Limitless," the plot revolves around a super drug that greatly enhances intelligence — so much so that the main character develops a remarkably accurate and profitable stock forecasting system. To leverage his trading power, though, the protagonist turns to a loan shark for accelerated funds, setting up a central conflict in the narrative.
Of course, the film is preposterous. The loan shark is actually the smart one.
Such shady characters that live on the fringes of organized crime operate by discrete principles: compliance or consequences. That's it. And it's the same principle undergirding market sentiment. At the end of any given period, investors are either a net buyer of a security or they are not.
The fantasy depicted in "Limitless" is that patterns can be deciphered in the scalar continuous signal known as the share price. That would seem to be a practically impossible task. What's much more reasonable is to consider price as defined, discrete events that transition from one state of existence to another.
For example, in the past 20 weeks, ANET stock printed two sets of "4-6" sequences: four weeks of upside interspersed with six weeks of downside, with a negative trajectory across the period. The last time this down-week-dominated trend materialized roughly two years ago, ANET enjoyed an extended bull run.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02153218/ANET-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-899991" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02153218/ANET-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02153218/ANET-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02153218/ANET-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02153218/ANET-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Also, it's worth pointing out that historically, the upside probability one week after the 4-6 sequence flashing stands at 68%. This stat suggests that investors tend to buy the dips in ANET stock. Assuming the positive pathway continues to hold, the projected upside target based on historical median trends would be around $97 to $98.
On the other hand, near-term risk exists between $88 to $89 under "normal" circumstances. With earnings next week, traders should be cognizant of the possibility of ugly surprises.
<h2 class="wp-block-heading">An Aggressive Bet for Impatient Traders</h2>
As prior trends suggest, ANET stock could see an early rise as a response to the 4-6 sequence, followed by a possible broad tapering effect in the later weeks. Therefore, traders who believe in the recurrence of behavioral dynamics may consider the 92/95 bull call spread expiring May 23.
This is an aggressive but rational wager based on the potential capabilities of ANET stock, involving the buying of the $92 call and simultaneous selling of the $95 call. Subsequently, the proceeds from the short call partially offset the debit paid for the long call, resulting in a net debit paid of $150. Should ANET rise through $95 at expiration, the maximum reward is also $150.
The beautiful part about this trade is that the security should be able to reach around $97 within the aforementioned time period, thus possibly providing some buffer.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/45121501/ibm-stock-big-blue-boring-but-compelling">Options Corner: Why Boring IBM May Be Ideal Tech Play To Ride Economic Chop</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

ANET

Options Corner: Smart Money Traders Charge In as Arista Networks Hits Potential Bounce Signal

WIIM

RNAZ

TransCode Therapeutics shares are trading lower after the company announced a 1-for-28 reverse stock split

Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) reported strong revenue and user growth in its better-than-expect Q1 report released Thursday. Executives offered more color and insight into future growth on the company's earnings <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45176569/reddits-ad-strategy-is-clicking-say-analystsstrong-q1-sets-stage-for-profitable-growth-in-2025">call with analysts. </a>
Q1 Details: Reddit beat analysts' expectations on the top and bottom lines <a href="https://www.benzinga.com/general/social-media/25/05/45151798/reddit-stock-soars-after-better-than-expected-q1-daily-active-uniques-up-31-ad-revenue-up-61-and-more">with earnings</a> of 13 cents per share and revenue of $392.36 million, which beat the analyst consensus estimate of $370.01. 
Read Next: <a href="https://www.benzinga.com/news/management/25/05/45140155/musk-shifts-focus-back-to-tesla-says-doge-will-endure-without-him-is-buddha-needed-for-buddhism?utm_source=articleShare">Musk Shifts Focus Back To Tesla, Says DOGE Will Endure Without Him: &#8216;Is Buddha Needed For Buddhism?&#8217;</a>
DAUs: The social platform also saw user growth of 31% year-over-year with 108.1 million daily active uniques.&nbsp;
Reddit CEO Steve Huffman said on the earnings call that Reddit had 400 million weekly active uniques in Q1, but does expect growth to be "bumpy" in the near term due to changes in Google's search ecosystem. Huffman added that DAU growth for April averaged in the high teens. 
However, the CEO expressed optimism for growth over the longer term.&nbsp;
"We believe we're in great shape over the medium and longer term. Look, ultimately, we drive growth when we make improvements to the product, which is where our focus is. So things like onboarding, search, machine translation, they all drive growth over the long term," Huffman told analysts.&nbsp;
Revenue: Reddit's ad revenue increased 61% year-over-year to $358.6 million, and other revenue increased 66% year-over-year to $33.7 million in the first quarter.&nbsp;
CFO Drew Vollero said on the earnings call that strength in ad impressions was the primary revenue driver, along with growth across various verticals and international markets. 
"Additionally, the increase in ad pricing from our investments in performance and targeting contributed to higher returns for advertisers," Vollero added.&nbsp;
Guidance: The CFO guided second-quarter revenue in the range of $410 million to $430 million, representing growth of&nbsp;46% to 53% year-over-year.&nbsp;
"We are confident in our ability to deliver strong growth in Q2 and beyond, given the positive momentum and investments we're making across product and sales,&#8221; Vollero said.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/45084982/sofi-brings-crypto-back-after-trump-policy-changes?utm_source=articleShare">SoFi Brings Crypto Back After Trump Policy Changes&nbsp;</a></li>
</ul>
Photo: Shutterstock

Social Media

Management

RDDT

Reddit Executives See 'Strong Growth In Q2 And Beyond'

HELE

Helen Of Troy Appoints Brian Grass As Interim CEO; Tracy Scheuerman Appointed Interim CFO

Telsey Advisory Group analyst Joseph Feldman on Friday <a href="https://www.benzinga.com/quote/COOK/analyst-ratings">reiterated a Market Perform</a> rating on the shares of Traeger Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) and lowered the price forecast from $2.50 to $2.00.
Traeger&#8217;s <a href="https://www.benzinga.com/pressreleases/25/05/b45149837/traeger-announces-first-quarter-fiscal-2025-results">first-quarter FY25 performance</a> met expectations, with revenues down 1.1%, surpassing the FactSet consensus of -3.0%. 
Adjusted EBITDA of $22.5 million slightly exceeded consensus but was below the company&#8217;s target of $24.0 million. Strong grill sales, up 13%, were driven by product launches like the Woodridge series. 
However, the company faces uncertainty from tariffs under the new Trump administration, as 80% of its grills are sourced from China, which faces a 45% tariff, according to the analyst.
Traeger has withdrawn its 2025 guidance due to uncertainty around tariff impacts.
Also Read: <a href="https://www.benzinga.com/news/25/05/45166629/wendys-q1-misses-revenue-estimate-lowers-2025-outlook-amid-us-sales-dip">Wendy&#8217;s Sizzles Abroad, But US Sales Leave Investors Cold</a>
Traeger faces significant tariff challenges, with a 45% tariff on grills from China and a 25% tariff on grills from Vietnam.
Accessories are subject to a 10% tariff from Taiwan, while the consumables business is not impacted. The company plans to offset these costs through cost-saving measures, sourcing diversification, and strategic price increases. 
The company is actively managing expenses by freezing hiring, deferring non-essential spending, and exploring additional cost-reduction opportunities for the year.
Traeger aims to shift most Chinese manufacturing to other countries by 2026.
Traeger plans to leverage its brand strength, premium positioning, and innovation to maintain pricing power despite inflation, expecting other grill brands to also raise prices.
However, tariffs and macroeconomic challenges are likely to pressure short-term performance, the analyst noted.
Traeger is adopting a cautious inventory strategy amid macroeconomic and tariff uncertainties, reducing purchase orders to align with demand. The company has pre-tariff products in stock, which will help offset cost pressures temporarily. 
For 2025, the analyst has lowered sales forecast to (1.4%) to $596 million from (0.3%) to $605 million previously.
Price Action: COOK shares traded lower by 1.3% at $1.46 on Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45170433/kimberly-clark-commits-2b-to-us-expansion-overhaul">Kimberly-Clark Commits $2 Billion For US Expansion Overhaul</a></li>
</ul>
Photo: Shutterstock

Reiteration

COOK

Traeger Faces Tariff Uncertainty As 80% Of Grills Come From China, Says Analyst

PLRZ

Polyrizon shares are trading higher after the company announced its planned reverse split will not be effected.

Helen Of Troy Chief Executive Officer Noel Geoffroy To Depart From The Company, Effective Immediately; CFO Brian Grass Has Been Appointed Interim CEO

CNO Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) announced today that its Board of Directors has approved a $0.01 per share increase in its quarterly dividend, its thirteenth consecutive annual increase. The Board declared a quarterly cash dividend of $0.17 per share on the company's common shares. The dividend will be payable June 24, 2025, to shareholders of record at the close of business on June 10, 2025.&nbsp;

Dividends

CNO Financial Group Raises Quarterly Cash Dividend From $0.16 To $0.17 Per Share

Betterware de México, S.A.P.I. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) ("BeFra" or the "Company"), announced that after the shareholders meeting held on April 30, 2025, the payment of an aggregate dividend of MX $200,000,000 has been approved. This amount represents approximately US $0.2736 per share before applicable tax withholdings, or approximately US $0.2463 per share after applicable tax withholdings. The dividend is payable on May 23, 2025 to shareholders of record as of May 12, 2025.

BWMX

BeFra Announces Dividend Payment Of 200 Million Mexican Pesos, ~$0.2463 Per Share After Applicable Tax Withholdings

Offerings

USCB

USCB Financial Holdings Files For Mixed Shelf Of Up To $100M

Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) has outperformed the market over the past 20 years by 6.54% on an annualized basis producing an average annual return of 14.77%. Currently, Parker Hannifin has a market capitalization of $79.71 billion. 
Buying $100 In PH: If an investor had bought $100 of PH stock 20 years ago, it would be worth $1,548.32 today based on a price of $619.02 for PH at the time of writing.
<h3>Parker Hannifin's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746216940_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Parker Hannifin Stock In The Last 20 Years

Barrington Research analyst Kevin Steinke maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Outperform and maintains $10 price target.

QUAD

Barrington Research Maintains Outperform on Quad/Graphics, Maintains $10 Price Target

Barrington Research analyst Alexander Paris maintains Interface (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) with a Outperform and maintains $30 price target.

TILE

Barrington Research Maintains Outperform on Interface, Maintains $30 Price Target

Bon Natural Life Receives Nasdaq Notice For Non-Compliance With Listing Rules

Press Releases

180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

Elray Resources Announces Strategic Sale of Crypto iGaming Technology

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

180 Life Sciences Corp. Announces Share Repurchase

Legal

180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction

Comments

180 Life Sciences

180 Life Sciences (ATNF) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌